Esketamine Therapy in Tamarac, FL

Compassionate Care with Esketamine Therapy

Esketamine therapy (SPRAVATO®) is an FDA-approved nasal spray for adults with treatment-resistant depression. SPRAVATO® is also approved with an oral antidepressant for adults with major depressive disorder (MDD) experiencing acute suicidal ideation or behavior.

A mental health clinican might recommend medications and psychotherapy as first-line treatment, but for some people these treatment options may not provide substantial relief. In such cases, your mental healthcare provider may assess and advise Esketamine for depression.

IsmailMD offers evidence-based Spravato treatment in Tamarac, FL, under the supervision of board-certified professionals, serving patients with depression from Coral Springs, Margate, Coconut Creek, and communities across South Florida.

Understanding Esketamine Therapy

Conventional depression treatments may take weeks or months to show results. Depression that does not respond to medications and psychotherapy is known as Treatment-resistant depression. Studies reveal that Spravato treatments are effective in such cases.

Spravato is the brand name for Esketamine nasal spray, the approved medication for treatment-resistant depression, and should be administered under the supervision of a qualified mental healthcare provider in a certified Spravato clinic, with at least two-hour clinical monitoring.

IsmailMD is a certified Spravato clinic for depression and adheres to all FDA regulations and patient safety measures.

Esketamine Nasal Spray: How It Works for Depression

Esketamine therapy is an advanced depression treatment that the FDA has approved with a distinct mechanism of action. It is an NMDA receptor antagonist that affects glutamate signaling in the brain. These effects may contribute to changes in neural connections and help reduce depressive symptoms.

Esketamine treatments at Ismail MD may help reduce depressive symptoms in patients with treatment-resistant depression and major depressive disorder who have suicidal thoughts or ideation.

Studies show that Spravato for depression has shown reductions in depressive symptoms and remission in some patients where other treatments fail. Effectiveness, however, varies for every individual.

The Esketamine Treatment Process

At IsmailMD, Esketamine treatment has the following essential steps.

Initial Psychiatric Evaluation

Our board-certified mental health clinicians will assess and evaluate your condition before each SPRAVATO treatment session.

The evaluation may include:

Current symptoms, their severity, and condition.
Current medications or supplements.
History of previous treatments.
Medical history and relevant coexisting conditions
Psychiatric history.

Treatment Preparation

Once you are considered for Esketamine treatments, the mental health clinical team will explain the procedure to you, check your vitals, and review your current medications. Our team focuses on patient safety and helping you feel comfortable before, during, and after the procedure.

Nasal Spray Administration

Spravato depression treatment is self-administered. It is designed only as a nasal spray and is not available in any other form, such as an injection, for depression.

Staff will explain how to use the spray. While you administer the recommended dose, the clinician will be present for supervision.

Post-Treatment Monitoring

Spravato (Esketamine for depression) requires at least a two-hour post-treatment monitoring period, in accordance with the Risk Evaluation and Mitigation Strategy (REMS), during which our clinical staff monitors vitals and checks for signs of dizziness, sleepiness, nausea, changes in blood pressure, or dissociation.

Once the healthcare provider determines that your condition is appropriate for discharge, you can leave. Plan transportation for safety; do not drive yourself.

Ideal Candidates for Esketamine Therapy

Spravato is a relatively new depression treatment that the FDA has approved. A healthcare professional determines whether SPRAVATO is appropriate based on the person’s diagnosis, treatment history, medical history, current symptoms, and other factors.

Adults with treatment-resistant depression.
Adults with MDD and acute suicidal ideation or behavior, when SPRAVATO® may be used as monotherapy or in combination with an oral antidepressant.
Adults who have not experienced adequate improvement with previous depression treatments.
Patients who can attend scheduled treatment sessions and complete the required post-treatment monitoring.

Esketamine Side Effects and Safety Precautions

The common short-term side effects of Esketamine therapy include the following,

Common or frequently reported effects may include:

Dizziness
Nausea
Dissociation
Increased blood pressure
Sleepiness
Headache

Important safety risks include:

Sedation
Respiratory depression
Increased blood pressure
Cognitive impairment
Abuse and misuse

Frequently Asked Questions About Esketamine Therapy

What is Esketamine therapy?

Esketamine therapy is an FDA-approved treatment for TRD and major depressive disorder patients with suicidal ideation and thoughts. It can only be advised by a healthcare provider and is self-administered under a clinician’s supervision.

Is SPRAVATO the same as ketamine spray?

SPRAVATO® contains Esketamine. Although Esketamine is related to ketamine, SPRAVATO® is a distinct FDA-approved medication with specific indications, dosing requirements, and a REMS safety program.

Is Esketamine a new depression treatment?

Esketamine is a relatively new treatment option that is approved as a nasal spray with specific uses, REMS, and a mechanism. If you or someone you know is experiencing an immediate risk of suicide or is in a mental health emergency, call 911 or seek emergency medical care. SPRAVATO® treatment does not replace emergency or inpatient care when clinically necessary.

Is nasal ketamine for depression FDA-approved?

SPRAVATO® (esketamine) is the FDA-approved nasal spray indicated for specific depression-related uses. Traditional ketamine itself is not FDA-approved for treating psychiatric disorders.

Is intranasal Spravato the only way to deliver Spravato for treatment resistant depression?

SPRAVATO is only administered intranasal. Unfortunately, the effectiveness and predictability of response, and the overwhelming majority of scientific studies of SPRAVATO for depression and mental health conditions, have been performed using intranasal SPRAVATO. In short, intranasal SPRAVATO is the gold standard route for SPRAVATO administration.